SK Biopharmaceuticals and Insilico Medicine have entered a research and development collaboration to discover drug candidates for neuroimmune disorders of the central nervous system.

• Technology Application: Insilico Medicine will use its Pharma.AI platform for target validation, generative chemistry and molecule optimisation to support candidate discovery and design.
• Development Responsibilities: Insilico Medicine will lead drug discovery activities, while SK Biopharmaceuticals will oversee late-stage development and commercialisation of resulting programmes.
• Therapeutic Focus: The collaboration targets neuroimmune central nervous system disorders, including neuroinflammatory, neurodegenerative and rare neurological conditions.

This summary is based on a news report published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.